[Correspondence] Tracking the spread of avian influenza A(H5N1) with alternative surveillance methods: the example of wastewater data

Di |2024-08-03T00:30:01+02:00Agosto 3rd, 2024|Categorie: Coronavirus Lancet|

The global health landscape is currently dominated by the threat of avian influenza, a public health challenge of unprecedented magnitude. We are on the brink of a potential crisis, where pandemic risk is severely underestimated and efforts to prepare ...

[Articles] Two dose levels of once-weekly fosravuconazole versus daily itraconazole in combination with surgery in patients with eumycetoma in Sudan: a randomised, double-blind, phase 2, proof-of-concept superiority trial

Di |2024-08-02T00:30:01+02:00Agosto 2nd, 2024|Categorie: Coronavirus Lancet|

Treatment with either dose of fosravuconazole was not superior to itraconazole, and the two doses had a numerically lower efficacy. However, fosravuconazole presented no new safety signals, and its lower pill burden and reduced risk of drug–drug intera...

[Articles] Two dose levels of once-weekly fosravuconazole versus daily itraconazole in combination with surgery in patients with eumycetoma in Sudan: a randomised, double-blind, phase 2, proof-of-concept superiority trial

Di |2024-08-02T00:30:01+02:00Agosto 2nd, 2024|Categorie: Coronavirus Lancet|

Treatment with either dose of fosravuconazole was not superior to itraconazole, and the two doses had a numerically lower efficacy. However, fosravuconazole presented no new safety signals, and its lower pill burden and reduced risk of drug–drug intera...

[Articles] Safety and immunogenicity of the live-attenuated hRVFV-4s vaccine against Rift Valley fever in healthy adults: a dose-escalation, placebo-controlled, first-in-human, phase 1 randomised clinical trial

Di |2024-07-26T00:30:01+02:00Luglio 26th, 2024|Categorie: Coronavirus Lancet|

The hRVFV-4s vaccine showed a high safety profile and excellent tolerability across all tested dose regimens, eliciting robust immune responses, particularly with the high-dose administration. The findings strongly support further clinical development ...

[Correspondence] Mortality of H5N1 human infections might be due to H5N1 virus pneumonia and could decrease by switching receptor

Di |2024-07-25T00:30:02+02:00Luglio 25th, 2024|Categorie: Coronavirus Lancet|

The increasing host range and ability of avian influenza viruses to spread between mammals and humans raises concerns about a potential pandemic risk.1 This pandemic risk is a concern as the mortality was 458 (52%) of the 876 influenza A(H5N1) cases re...

[Correspondence] Mortality of H5N1 human infections might be due to H5N1 virus pneumonia and could decrease by switching receptor

Di |2024-07-25T00:30:02+02:00Luglio 25th, 2024|Categorie: Coronavirus Lancet|

The increasing host range and ability of avian influenza viruses to spread between mammals and humans raises concerns about a potential pandemic risk.1 This pandemic risk is a concern as the mortality was 458 (52%) of the 876 influenza A(H5N1) cases re...

[Correspondence] Recombination as an evolutionary driver of MERS-related coronavirus emergence

Di |2024-07-25T00:30:01+02:00Luglio 25th, 2024|Categorie: Coronavirus Lancet|

In their study, Alimuddin Zumla and colleagues1 highlighted the potential threat of MERS-related coronaviruses (MERSr-CoV, subgenus Merbecovirus) to global health. A key concern is the ability of the virus to use diverse cell entry receptors, including...

[Correspondence] Recombination as an evolutionary driver of MERS-related coronavirus emergence

Di |2024-07-25T00:30:01+02:00Luglio 25th, 2024|Categorie: Coronavirus Lancet|

In their study, Alimuddin Zumla and colleagues1 highlighted the potential threat of MERS-related coronaviruses (MERSr-CoV, subgenus Merbecovirus) to global health. A key concern is the ability of the virus to use diverse cell entry receptors, including...

[Correspondence] Alarming Plasmodium falciparum resistance to artemisinin-based combination therapy in Africa: the critical role of the partner drug

Di |2024-07-23T00:30:01+02:00Luglio 23rd, 2024|Categorie: Coronavirus Lancet|

Artemisinin-based combination therapy (ACT) has been the mainstay for uncomplicated Plasmodium falciparum malaria globally for over 15 years. ACT was considered crucial to prevent the development of resistance to either compound, but it did not prevent...

Torna in cima